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Glaucoma is characterized by the death of retinal ganglioncells (RGCs) and loss of vision. It is the second most
frequent cause of irreversible blindness in the world and af-
fects primarily the older population.1 Projections of prevalence
show that by 2020 there will be an estimated 79.6 million
people worldwide with glaucoma, with a higher proportion of
women than men.1 Glaucoma can be treated but is not yet
curable. Treatments currently available, such as the daily ad-
ministration of eye drops, lead to high levels of noncompli-
ance, especially in the aged population. In several laboratories,
including ours, intense research is ongoing to search for alter-
native treatments of the disease. Using genes, we seek to
develop gene drug therapies that can be many times more
efficient than conventional drugs and allow less frequent ad-
ministration—perhaps just once every 1 or 2 years. In cases of
inherited glaucoma caused by either recessive or dominant
genes, we seek gene replacement and gene knockdown strat-
egies that could reverse the undesired outcome of the muta-
tion. Technology for this new state-of-the-art treatment is cur-
rently available and has been successfully applied in other
diseases, including conditions in the eye.2
Most glaucomas are induced by dysfunction of the trabec-
ular meshwork (TM) tissue, which in turn leads to increased
resistance to aqueous humor outflow and elevated intraocular
pressure (IOP). The mechanism by which elevated IOP dam-
ages the posterior RGCs is not fully understood. Whether the
elevated IOP first damages the RGC axons and then causes the
cell body to die or it damages the cell body first, which then
causes the axons to die is a subject of intense deliberation.
Although elevated IOP is not the only factor causing RGC
death, it is the most common. All currently available drugs that
lower IOP slow the progression of all glaucomas, even the form
referred to as normal-tension glaucoma.
Because of this particular physiology, there are two main
avenues to follow in approaching research in gene therapy for
glaucoma. The first entails targeting the RGCs with the goal of
promoting their survival and protecting them against glauco-
matous insults (neuroprotection). The second entails targeting
the TM with the goal of lowering IOP.
Gene therapy vectors deliver the genetic material to the
inside of the cells. Because viruses have been selected during
evolution to cleanly and efficiently enter living cells, they have
emerged as excellent carriers of any desired genetic material.
Given the tools of molecular biology and recombinant DNA
that are now available, a virus can be specially engineered both
to remove the potentially deleterious sequences from its ge-
nome and to insert the beneficial foreign sequences to be
delivered to the target cell.
ADVANCES IN PROTECTION OF RGCS BY
GENE THERAPY
Gene delivery to the RGC is achieved by a single intravitreal
injection through the corneal limbus. The viral vector of
choice is adeno-associated virus (AAV). This small virus (19–26
nm) is nonpathogenic and confers safe and long-term expres-
sion of the transgene. It has been used as a vector to deliver the
corrected version of the RPE65 gene, which is mutated in
animals and humans with Leber’s congenital amaurosis, a blind-
ing eye disease. In clinical trials, the gene delivered to the
subretinal space by a viral vector restored vision in patients.2
Animal Studies of Delivery of Cell Survival Genes
to the RGCs
Because of the vector’s proven safety and efficiency, several
laboratories have injected AAV2 carrying neurotrophins, anti-
apoptotic genes, or defense genes, into the eyes of rat models
of glaucoma. As early as 2002, Di Polo’s laboratory (Lebrun-
Julien and Di Polo3) in Canada showed that co-injecting AAVs
carrying brain-derived neurotrophic factor and its receptor
TrkB increased the number of surviving RGCs by 76%. Similar
experiments using different rat and mouse models of glaucoma
have validated the initial findings. McKinnon et al.4 showed
that an AAV2 construction carrying the caspase inhibitor bac-
ulovirus IAP repeat–containing protein (BIRC4) led to a 53%
survival of optic nerve axons in the rat after chronic exposure
to elevated IOP.4 In 2009, Quigley, Hauswirth, and coworkers
(Pease et al.5) reported protection of RGC axons by delivering
AAV2/ciliary-derived neurotrophic factor to rats. Cao’s labora-
tory (Zhou et al.6) showed that AAV2/pigment epithelium–
derived factor protects the axons of the DBA/2J glaucoma
mouse. An important leap in gene therapy protection of RGCs
was recently published. Work in Rex’s laboratory (Sullivan et
al.7) showed for the first time that systemic administration of a
neuroprotective molecule can lead to RGC protection in the
DBA/2J glaucoma mouse. The investigators injected AAV2/5
carrying a mutated version of a multiple neuronal protection–
encoding gene (erythropoietin R76E; AAV2/5.CMV.EpoR76E)
into the quadriceps of the mouse before the animal developed
glaucoma. By 10 months of age, when the disease develops in
this mouse model, the RGC somata as well as their axons and
visual function were protected when compared to controls
given AAV2/5 reporter vectors.7 In addition, the systemically
delivered mutated gene reduced the toxic side effect of the
parent gene and maintained normal hematocrit levels (percent-
age of red blood cell volume). These encouraging findings
show that research is leading to less toxic and more patient-
friendly administration of neuroprotectants as potential adjunc-
tive therapy for glaucoma.
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New Technology for Longitudinal Evaluation of
RGC Survival
Important advances in imaging technology have allowed for
the measurement of the progression of RGC survival in the
same animal. Because of the existing significant variation in
individual measurements, the relevance of developing imaging
methods that observe changes longitudinally in each living
animal is very high. Such technologies not only bring a higher
degree of reliability and accuracy to animal research but have
potential applications in the clinical setting, including the di-
rect counting of fluorescently labeled RGCs using a confocal
scanning laser ophthalmoscope (cSLO) and the assessment of
the thickness of the nerve fiber layer of the retina using spec-
tral domain optical coherent tomography (SD-OCT). These
new, emerging imaging evaluations will, in addition, consider-
ably reduce the number of animals needed for a single study
and the cost associated with their maintenance.
ADVANCES IN THE TREATMENT OF THE TM TO
LOWER IOP BY GENE THERAPY
During the past few years, treatment of the TM by gene therapy
has shown major progress due to the use of replication-defi-
cient recombinant adenoviral (Ad) vectors. In contrast to the
AAV vectors that do not transduce the TM, the Ads have a very
high tropism for all cells of the outflow tissue in all animal
species tested, from human donor eyes to eyes of monkeys,
rabbits, rats, and mice. Although the drawback of the Ad
vectors is the limited length of expression of the transgene and
their induction of an inflammatory response at high concen-
trations, the combination of their simple engineering, large-
capacity, high-tropism infection of nonreplicating cells and no
genome integration makes them ideal for preclinical studies
targeting the TM. Ad vectors have allowed the determination of
the effect of a transgene in outflow facility and the identifica-
tion of relevant cellular pathways and of regulatory expression
elements. Ad vectors have also allowed the development of
new elevated IOP models that do not destroy the trabecular
tissue. Gene delivery to the TM is achieved by a single intra-
cameral or intravitreal injection through the corneal limbus.
Preclinical Studies of the Delivery of Target
Genes with Adenoviral Vectors
Identification of Genes and Biological Pathways In-
volved in IOP Regulation. One of the first genes and path-
ways identified by the use of Ads was the small GTP-binding
protein RhoA. When a dominant-negative RhoA gene was in-
serted into the Ad vector, it switched the wild-type protein for
the mutated, inactive RhoA and reduced the IOP of perfused
human eyes in organ cultures.8 The involvement of this path-
way, where the activation of RhoA leads to the activation of
Rho kinase (ROCK) and ends in the reorganization of the actin
cytoskeleton, has been independently sought and validated in
numerous laboratories.9 Presently, development of chemical
RhoA pathway inhibitors (specifically of ROCK) is being pur-
sued by several pharmaceutical companies as potential drugs
for glaucoma. The development of a gene therapy drug carry-
ing the inhibitor gene is likely to come later, after the regula-
tory elements that control gene expression have been fully
worked out.
The use of recombinant Ads has further contributed to the
identification of two other TM cellular pathways relevant to
glaucoma: the presence of an ongoing calcification process and
the involvement of the Wnt signaling pathway. We have shown
that an Ad virus carrying the inhibitor of calcification matrix
Gla gene (Adh.MGP) inhibits bone morphogenetic 2 (BMP2)–
induced mineralization in TM cells.10 For the involvement of
the WNT signaling pathway, Clark’s group (Wang et al.11)
injected an Ad virus carrying the gene encoding the WNT
antagonist secreted frizzled-related protein 1 (SFRP1) in the
mouse eye. SFRP1 induced an elevation of pressure that was
reversed by the administration of the inhibitor GSK. The exis-
tence of these two pathways in TM physiology opens the door
to the development of new therapeutic targets for glaucoma.
Thus, replenishing a low MGP expression during early glau-
coma or helping restore a functional WNT pathway could delay
the progress of the disease.
Insertion of Regulatory Elements for Expressing
Therapeutic Genes Only When Needed. In a gene therapy
regimen in which genes serve as drugs, a system must be in
place that allows the expression of the gene only when it is
needed. Advances have been made on vectors carrying induc-
ible regulatory sequences in the promoter of potentially ther-
apeutic genes. In the most successful study to date, an Ad
vector developed for the treatment of steroid glaucoma carried
the matrix metallopeptidase 1 (MMP1) gene regulated by glu-
cocorticoid response elements (Adh.GRE.MMP1). Intracameral
injection of this vector in a model of steroid glaucoma in sheep
not only reduced elevated IOP but also prevented its eleva-
tion when injected 2 days before the steroid was applied
(Fig. 1).12,13 This coupled study has provided the first in vivo
proof of concept and has established the basis for further
development of this treatment.
Other studies using pressure-regulatory elements as well as
elements that confer TM tissue preference in Ad vectors are in
the pipeline and have been reported at recent scientific meet-
ings. The promoter of the MGP gene has been fused to the
gene encoding secreted alkaline phosphatase and perfused
into human donor eye cultures. Induction of elevated pressure
in one of the two paired eyes resulted in higher secretion of the
reporter enzyme (Carabana J, et al. IOVS 2011;52:ARVO E-Ab-
stract 4623). This finding indicates that the MGP promoter
elements respond to elevated IOP. Therefore, these sequences
could be inserted in front of different therapeutic genes, reg-
ulating them to produce their therapeutic protein only when
IOP is high. In another study, the promoter of the B-crystallin
gene was fused to a reporter gene that, when expressed, turns
blue through an enzyme reaction, thus making it easy to detect
in the tissue. This promoter delivered its transgene to a partic-
ular region of the TM known for its relevance in offering
resistance to the flow of eye fluid, the juxtacanalicular region
(Spiga M, et al. IOVS 2008;49:ARVO E-Abstract 1612).14 Eluci-
dation of the parameters that control gene expression will
make possible the application of gene therapy technology in
the treatment of glaucoma.
Generation of Animal Models of Elevated IOP by Ad
Gene Transfer. Another important advance in work on Ad
gene delivery to the TM has been the generation of elevated
IOP animal models for the evaluation of conventional and/or
gene therapy drugs. Most of today’s animal models of elevated
IOP glaucoma are obtained by scarring or destroying the TM
tissue by different means. Although such models are adequate
for the study of neuroprotection of the RGCs, they are of no
use in studying therapeutic targeting of the TM. We reasoned
that delivering genes that produce a thicker, denser extracel-
lular matrix would slow the flow of the eye fluid when exiting
the eye through the TM. We found that a single injection of an
Ad vector carrying the mineralization protein BMP2 into the
anterior chamber of rats significantly induced an elevation of
IOP for at least 6 weeks after injection (Buie L, et al. IOVS
2009;50:ARVO E-Abstract 4841). Another Ad virus carrying the
extracellular matrix deposition stimulator and known glauco-
ma-associated factor, transforming growth factor beta 2
(Ad.hTGF2), also elevated IOP in rodents.15 The IOP increase
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occurred only when a bioactivated, mutated form of TGF2,
rather than the wild type, was delivered; the effect lasted for
approximately 3 weeks. The investigators also showed a cor-
relation between the increase in IOP and a decrease in outflow
facility, thus clearly implicating the TM. The success of this
strategy of creating elevated IOP models by gene transfer, now
validated in two different laboratories, is going to have great
impact in the near future for gene therapy. It will open the
door, not only to different types of models, but to the oppor-
tunity of generating large animal models consecutively—that
is, the possibility of using the same large animal for the gener-
ation of different models.
ADVANCES USING ADDITIONAL GENE
DELIVERY APPROACHES
Lentiviral Vectors for Glaucoma Gene Therapy
Lentiviral vectors are derived from immunodeficiency viruses.
The available vectors have originated from human, simian, and
feline viruses (HIV, SIV, and FIV) and are depleted of poten-
tially dangerous virus replication genes. Although somewhat
more difficult to work with because of low titers and psycho-
logical concerns, these vectors deliver transgenes to the RGCs
and TM very efficiently.16 They are single-stranded RNA vi-
ruses, and, on infection, they integrate the cell’s DNA by
reverse transcription. The immediate consequences of this
property are the possibilities of disrupting a vital gene by
random insertion and of obtaining long-term expression of the
transgene. A very recent example of an SIV vector carrying the
neuroprotective molecule human PEDF and injected subreti-
nally into rats showed protection of the number of RGCs and
of their function in two models of glaucoma.17 In normoten-
sive cats, FIV vectors carrying different prostaglandin pathway
enzymes with optimized codons were co-injected intracamer-
ally. Injections of single vectors did not have much effect on
IOP, but the combination cyclooxigenase-2 with other prosta-
glandin pathway enzymes induced and maintained an IOP
reduction for more than 5 months.16,18
Delivery of Nonviral Short-Interference (si)RNA
and Nanoparticles
An alternative gene therapy approach without the use of viral-
based vectors entails the use of siRNA—short (21 nt), double-
stranded RNA oligonucleotide chains that can silence the trans-
lation of a specific mRNA. These specific sequences targeting a
given gene can be determined by using bioinformatics tools
and can be synthesized in a laboratory. The goal of delivering
siRNA to a cell or tissue is to silence an unwanted gene
temporarily. In general, an siRNA molecule needs some help to
enter the cell. Thus, a concerted research effort is ongoing in
the area of nanotechnology that aims to increase and target
drug delivery to the eye. Nanoparticles of different polymer
compositions, including magnetic nanoparticles, are being
coupled to siRNAs (as well as to genes, antibodies, and peptide
factors) to facilitate entrance. These nanoparticles are being
delivered to the front and back of the eye and assayed for
functional delivery.19 A few studies, however, have demon-
strated that a naked siRNA molecule can, by itself, penetrate
human TM tissue when perfused at physiological pressure.20 In
our laboratory, perfusion of the glucocorticoid receptor naked
siRNA not only silenced this gene but blocked the induction of
other downstream genes induced by glucocorticoids in the
TM.20 Continuation experiments to deliver naked siRNA to the
TM in a living animal have been encouraging. At the last ARVO
annual meeting, a study was presented in which topical admin-
istration of a commercial naked siRNA lowered IOP in clinical
trials (Ruz V, et al. IOVS 2011:52 ARVO E-Abstract 223).
Preparing to Target the TM with Clinically
Tested Vectors
To date, there have been 12 clinical trials using gene therapy
viral vectors for the treatment of ocular diseases in the United
States and less than 5 worldwide (Journal of Gene Medicine
Clinical Trial database: http://www.abedia.com/wiley/index.
html; updated January, 2012). Of the 12 U.S. studies, 6 involved
AAV2 vectors. The greatest success has been achieved with the
replacement of the RPE65 wild-type gene in blind patients
FIGURE 1. Reduction of steroid-
induced elevated IOP in sheep
treated with gene therapy vector
Adh.GRE.MMP1.
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with Leber’s congenital amaurosis who carry a mutation in the
gene.21,22 The AAV2.RPE65 was administered by subretinal
injection into a single eye, and patients showed significant
vision improvement in dim light with no safety issues. Efficacy
and safety have been sustained for up to 4 years and readmin-
istration of the same virus to the second eye of three adult
patients resulted in improvement of retinal visual function and
visual cortex activation.21 This important success has in itself
validated the use of AAV viral vectors in gene therapy for the
eye. AAVs transduce the RGCs very efficiently, but as men-
tioned, they do not transduce the TM. Studies to elucidate the
cellular mechanism responsible for such lack of transduction
led us to the discovery that, in contrast to what we originally
thought, the virus did not have any problem entering the TM
cell. The limitation occurs one step downstream of the infec-
tion cycle, where the virus first replicates its single-stranded
DNA and then transcribes and translates the transgene.23 The
development at the University of North Carolina Gene Therapy
Center of a second-generation AAV—self-complementary
(scAAV)—that circumvents the DNA replication-limiting step,
now allows safe and long expression in the TM. A single
injection of an scAAV2.GFP into a living monkey conferred
stable expression of the transgene for 2 years without eliciting
an inflammatory response.24
We thus have a clinical trial–tested vector for targeting the
main tissues involved in the development of glaucoma: the TM
and the RGCs. This puts us in a very favorable position to be
able to insert a therapeutic transgene in this vector and take it
to a clinical trial within a reasonable time frame.
ADVANCES IN IDENTIFYING GENE TARGETS FOR
LOWERING IOP
Glaucoma is a complex disease that is probably caused by
several genetic factors. Some of these factors are highly pene-
trant and have been detected through family-based genetic
linkage studies, whereas others have more modest overall
effect sizes and have been identified through large-scale whole-
genome association studies. Currently, 16 chromosomal loci
have been mapped, and four POAG genes have been identified
by linkage analysis.25 In addition, more than 25 genes have
been identified by candidate gene and gene association stud-
ies.26 The most studied highly penetrant glaucoma gene is
myocilin (a TM-inducible glucocorticoid response gene).27
There are more than 70 MYOC mutations, all associated with
elevated IOP, ranging from mild to severe (http://myocilin-
.com/; reviewed in Ref. 28). Myocilin mutations (albeit not a
single one) account for 36% of cases of the juvenile form of
the disease, but for only 3% of adult cases (http://myocilin-
.com/). Some, such as Gln368X, are typically associated with
adult-onset POAG,29 whereas others, such as Pro370Leu, are
nearly always associated with early onset.30 Because myocilin
mutations are autosomal dominant and most likely cause the
disease by a gain-of-function mechanism, the prospect of gene
therapy for a patient with a myocilin mutation would be a
combined gene knockdown and gene addition therapy. That
would involve the use of siRNA to block the mRNA of the mutant
allele and an overexpressed normal gene to boost the levels of
only one normal allele. It could be considered for the treatment of
a young patient whose high IOP would be a considerable bur-
den for the rest of his or her life and who would have a
significant chance of become blind. Recent advances in the
generation of transgenic mice with myocilin mutations and
elevated pressure could permit the development of an assay to
assess the safety and efficacy of such vectors in gene therapy.
In addition to the few genetically linked genes, numerous
sequencing and gene profile studies have identified a set of 50
potentially relevant genes that we have termed the biomarkers
or the molecular signature of glaucoma in the TM.31 These
genes have been identified in different laboratories, either as
highly abundant in the human tissue or highly regulated by
glaucomatous insults to the TM.31 They provide a starting point
for the development of gene therapy drugs to lower IOP. A
perfused organ culture comprehensive study involving human
genes whose expression is altered by elevated IOP revealed
that both an individual and a general response were present in
the human eye.32 General responder genes, such as MMP1,
angiopoietin-like 7, MGP, podoplanin, and the chemokine
CXCL2,32 are examples of good gene therapy candidates. A
cross-checked correlation of seven glaucoma-related categories
(gene abundance, response to glucocorticoids, TGF2, me-
chanical strain, glaucoma tissue sample transcription and pro-
teomics, and alteration by myocilin) stratified the biomarker
list by the number of insults that affected a given gene. These
categories may well be a representation of the genes most
likely to succeed in a gene therapy effort. The encouraging
results mentioned earlier from the studies of an MMP1 viral
vector lowering elevated IOP in sheep12,13 confer a degree of
confidence regarding the success of the project.
SUMMARY
The first question that can be posed is whether we are ready to
take a gene therapy vector to clinical trial for lowering IOP and
for glaucoma treatment. A recap of what we have and what we
need in order to achieve our goal leads to a seven-point plan on
how to proceed:
1. Make a decision about the type of glaucoma to treat.
There are several types of glaucoma: primary (including
juvenile) open-angle glaucoma, congenital, pseudoexfo-
liation, and steroid. We cannot address all of these at the
same time. We will achieve better results if we focus first
on a particular type of glaucoma.
2. Selection of targets. Regardless of whether we are going
to try the gene knockdown/addition route or the gene
therapy drug approach, we should evaluate and select
which mutation or which genes (one- to two-gene drug)
we will develop first. We have good candidates.
3. Selection of vector pseudotype and route of adminis-
tration. Pseudotyping of the same virus or the ability to
incorporate different targeting proteins in its envelope
can significantly affect the tropism of the virus for a
given cell type. Now that the general safety of the AAV
vector has been established in the human (so far, up to
4 years),2,21 a few pretrial studies are needed to deter-
mine which of the various virus pseudotypes would be
more specific for the TM. Further, the route of adminis-
tration for the TM, whether by intravitreal or intracam-
eral injection, must be validated.
4. Control of transgene expression by gene regulatory
elements. A long-term constitutive expression of a gene
inside a cell may not always be beneficial. The ideal gene
drug should have built-in signals that would allow a gene to
be turned on and off as needed. Ideally, these signals
would be automatic—that is, directly switched on by
a glaucomatous insult. They could also be induced by
the oral intake of the inducer.
5. Reliable animal efficacy evaluation procedures. Assays
to determine the effects of gene delivery as well as visual
function in animal models are critical. Fortunately, the
past 5 years have produced several instruments that
assess, for the first time, the physiological parameters
and noninvasive imaging morphometric determinations
in rodent eyes. Among them are the rebound tonometer,
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a very recent aqueous humor dynamics apparatus33; a
pattern electroretinogram to measure function in RGCs;
visual evoked potentials; and optical coherence tomog-
raphy.
6. Validation in different animal models. Testing of the
effect of the gene therapy vector, as with any conven-
tional drug, would require the confirmation of the effect
in more than one animal species. Again, during the past
2 to 3 years, the availability of TM animal models has
been improving. There are new strategies for using gene
transfer (BMP2 or TGF2 genes) or microbeads in the
creation of an animal model of elevated pressure that
does not destroy the TM. The advantage of these strate-
gies is the possibility of generating large animal models
without the expense required in the creation of trans-
genic animals.
7. Validation in different laboratories. It is essential that
researchers in different laboratories independently vali-
date results.
From the discussion of this plan by the panel of glaucoma
investigators emerged the idea of forming a consortium among
a few centers with the focused goal of moving toward the
treatment of glaucoma by gene therapy.
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